Subscribe to our email list for the latest updates
Subscribe to our email list for the latest updates
Also known as PRnT™, the treatment uses highly localized radiation to destroy cancerous tumors by placing a radioactive isotope directly inside the treatment area, delivering therapeutic radiation from within the tumor. Vivos Inc. has developed a Yttrium-90 based injectable device to treat tumors in animals (IsoPet® Division) and humans (RadioGel® Division, not currently approved for human use).
Radionuclide therapy, also known as nuclear medicine therapy or radiopharmaceutical therapy, involves the use of radioactive substances to treat diseases, most commonly cancer. The therapy utilizes radionuclides, which are radioactive isotopes, attached to molecules that can specifically target cancer cells. This allows the radionuclides to deliver targeted radiation directly to the tumor or diseased area, minimizing damage to surrounding healthy tissue.
In this treatment, the radioactive isotopes emit radiation that damages the DNA of the targeted cells, leading to cell death or a significant reduction in the cell's ability to multiply. The most familiar forms of radionuclide therapy include treatments for thyroid cancer using iodine-131, pain relief from bone metastases with strontium-89 or samarium-153, and peptide receptor radionuclide therapy (PRRT) for treating neuroendocrine tumors using radionuclide peptides. Vivos Inc. and their patented Precision Radionuclide Therapy™ uses Yttrium-90 to kill tumors and is revolutionizing the treatment of cancer.
RadioGel® is currently not approved for human therapy by the FDA. Human trials are taking place in India.
Direct Interstitial Treatment of Solid Tumors Using an Injectable Yttrium-90-Polymer Composite
Purpose: Yttrium-90 (90Y)-polymer composite (RadioGel®) may be administered directly into cancerous tissues to deliver highly localized beta radiation for therapy. In a dose-escalation study, the authors investigated the feasibility of treating feline and canine soft-tissue sarcomas as a model for non resectable solid tumors in humans to gain clinical experience and to identify optimal methods for placing the composite uniformly within target tumor tissue.
Bangalore, India